What is the 13F Pro Quality Score for BDX?

13F Pro ranks BECTON DICKINSON & CO (BDX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BDX's current score at https://13fpro.ai/research/BDX (free sign-up required for the full ranking).

Where does 13F Pro source BDX data?

All BECTON DICKINSON & CO fundamentals and ownership data come directly from SEC EDGAR. BECTON DICKINSON & CO files with the SEC under CIK 10795. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BDX in?

BECTON DICKINSON & CO (BDX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BDX research updated on 13F Pro?

BDX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BECTON DICKINSON & CO(BDX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 10795 BDX stock profile & AI dashboard →

13F Pro Quality Score

50.7/100

Rank #1,437 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

35.7/100

Profitability

42.5/100

Balance Sheet

49.6/100

Earnings Quality

14.3/100

Free Cash Flow

65.7/100

Institutional Flow

10.1/100

Revenue Scale

92.8/100

Dilution Risk

52.9/100

BDX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BECTON DICKINSON & CO (BDX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BDX at 50.7/100 on a 32-signal composite quality model, placing it at rank #1,437 of 2,879 stocks — the top half of the AI-ranked universe. BDX scores in the top quartile across revenue scale (92.8). Areas of concern include institutional flow (10.1) and earnings quality (14.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), BECTON DICKINSON & CO reports quarterly revenue of $4.7B, net income of $-311.0M. Top institutional holders of BDX by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. BDX trades on the NYSE exchange and files with the SEC under CIK 10795. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BECTON DICKINSON & CO directly from SEC EDGAR. BECTON DICKINSON & CO's 13F Pro composite quality score has ranged between 8 and 68 since 2021, currently 50.7 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about BECTON DICKINSON & CO

Quirks, history, and lore behind BDX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · large-cap · listed on the NYSE · headquartered in New Jersey.
2
The Numbers
Annual revenue of roughly $20 billion, with operations spanning 190+ countries — it's one of the largest medical technology companies on the planet.
3
The History
Founded in 1897, it has been making needles and syringes longer than most companies have existed, and it helped standardize those products for modern medicine.
4
The Secret
It's quietly one of the world's biggest suppliers of prefillable drug delivery systems and diagnostic instruments — the behind-the-scenes backbone of hospitals everywhere.
5
The Lore
Its 2017 acquisition of C.R. Bard for roughly $24 billion was one of the largest deals in medical device history, bolting on a full vascular and surgery portfolio overnight.
6
The Giveaway
Two last names, a century of syringes, and a ticker that sounds like a stock market sound effect — this is the company behind billions of vaccine injections every single year.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$4.7B

Net Income

Q2 2026

$-311.0M

ROIC

Q2 2026

0.2%

D/E Ratio

Q2 2026

0.72

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+2.7% YoY

$19.37BFY 2023

FY20 $16.07BFY21 $19.13BFY22 $18.87BFY23 $19.37B

Net Income

-16.6% YoY

$1.48BFY 2023

FY20 $874.0MFY21 $2.09BFY22 $1.78BFY23 $1.48B

Operating Income

-7.5% YoY

$2.11BFY 2023

FY20 $912.0MFY21 $2.25BFY22 $2.28BFY23 $2.11B

EPS (Diluted)

-16.0% YoY

$4.94FY 2023

FY20 $2.71FY21 $6.85FY22 $5.88FY23 $4.94

Total Assets

-0.3% YoY

$52.78BFY 2023

FY20 $54.01BFY21 $53.87BFY22 $52.93BFY23 $52.78B

Total Debt

-1.2% YoY

$15.88BFY 2023

FY20 $17.93BFY21 $17.61BFY22 $16.07BFY23 $15.88B

Op. Cash Flow

—FY 2023

FY20 $3.54BFY21 $4.65BFY22 —FY23 —

Metric	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$19.37B +2.7%	$18.87B -1.4%	$19.13B +19.0%	$16.07B -7.0%	$17.29B +8.2%	$15.98B
Net Income	$1.48B -16.6%	$1.78B -15.0%	$2.09B +139.4%	$874.0M -29.1%	$1.23B +296.5%	$311.0M
Operating Income	$2.11B -7.5%	$2.28B +1.4%	$2.25B +146.7%	$912.0M -48.2%	$1.76B +16.6%	$1.51B
EPS (Diluted)	$4.94 -16.0%	$5.88 -14.2%	$6.85 +152.8%	$2.71 -31.2%	$3.94 +556.7%	$0.60
Total Assets	$52.78B -0.3%	$52.93B -1.7%	$53.87B -0.3%	$54.01B +4.3%	$51.77B -4.0%	$53.90B
Total Debt	$15.88B -1.2%	$16.07B -8.8%	$17.61B -1.8%	$17.93B -7.5%	$19.39B -9.8%	$21.50B
Operating Cash Flow	—	—	$4.65B +31.3%	$3.54B +6.3%	$3.33B +16.2%	$2.87B

AI Insight: BDX Financial Trends

Revenue crashed 25% from Q4 2025 to Q1 2026 while the company swung to a $310M net loss, marking a dramatic deterioration.

• Revenue plummeted from $5,252M in Q4 2025 to $3,948M in Q1 2026, a 25% sequential decline.

• Company swung from $382M net income in Q4 2025 to a $310M net loss in Q1 2026.

• Operating income collapsed from $552M in Q4 2025 to just $10M in Q1 2026.

• Total debt decreased from $19,539M to $17,279M between Q4 2025 and Q1 2026.

⚠ Equity declined $1,149M from Q4 2025 to Q1 2026, the largest quarterly drop in the dataset.

⚠ Revenue volatility evident with Q4 quarters consistently weaker than Q3 peaks across multiple years.

AI Insight: BDX Ratio Trends

BDX margins collapsed dramatically in Q1 2026, with operating margin falling from 10.5% to 0.2% and the company posting its first quarterly loss.

• Operating margin crashed from 10.5% in Q4 2025 to 0.2% in Q1 2026, the lowest in the data series.

• Net profit margin turned sharply negative to -7.8% in Q1 2026 from 7.3% in the prior quarter.

• ROE swung from positive 6.0% in Q4 2025 to negative 5.1% in Q1 2026.

• ROIC plummeted from 4.9% in Q4 2025 to near-zero 0.1% in Q1 2026.

⚠ Q1 2026 represents an unprecedented operational breakdown requiring immediate investigation into underlying causes.

⚠ Debt-to-equity ratio improved slightly to 0.72 from 0.77, providing some financial flexibility during crisis.

Get alerted when BDX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BECTON DICKINSON & CO including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BDX

BlackRock, Inc.
$4.1B26,153,411 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.9B18,490,610 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.4B15,317,242 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$2.2B9,101,454 sh
STATE STREET CORP
$2.2B13,822,808 sh
First Eagle Investment Management, LLC
$1.9B11,928,111 sh
Invesco Ltd.
$1.6B10,174,327 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.1B7,107,263 sh
WELLINGTON MANAGEMENT GROUP LLP
$1.0B6,615,230 sh
FRANKLIN RESOURCES INC
$843.2M5,362,965 sh

Fund	Value	Shares
BlackRock, Inc.	$4.1B	26,153,411
VANGUARD CAPITAL MANAGEMENT LLC	$2.9B	18,490,610
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.4B	15,317,242
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$2.2B	9,101,454
STATE STREET CORP	$2.2B	13,822,808
First Eagle Investment Management, LLC	$1.9B	11,928,111
Invesco Ltd.	$1.6B	10,174,327
GEODE CAPITAL MANAGEMENT, LLC	$1.1B	7,107,263
WELLINGTON MANAGEMENT GROUP LLP	$1.0B	6,615,230
FRANKLIN RESOURCES INC	$843.2M	5,362,965

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BDX on your watchlist

Track score changes the day BECTON DICKINSON & CO files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BDX a good stock to buy?

13F Pro's AI-powered analysis of BECTON DICKINSON & CO (BDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BDX are available on the BDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BDX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BECTON DICKINSON & CO's investment landscape.